查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1412577

人类绒毛膜促性腺激素分泌市场：副产品、治疗领域和最终用户 - 全球预测 2024-2030

Human Chorionic Gonadotropin Market by Product (Naturally Extracted, Recombinant), Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermia Treatment), End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年人类绒毛膜促性腺激素分泌市场规模为12.7亿美元，预计2024年将达13.7亿美元，2030年将达21.1亿美元，复合年增长率为7.53%。

人类绒毛膜促性腺激素分泌的全球市场

主要市场统计
基准年[2023] 12.7亿美元
预测年份 [2024] 13.7亿美元
预测年份 [2030] 21.1亿美元
复合年增长率（%） 7.53%
人类绒毛膜促性腺激素市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估人类绒毛膜促性腺激素分泌市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出资讯的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对人类绒毛膜促性腺激素分泌市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵考察，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更资讯的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场并分析其在成熟细分市场的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-人类绒毛膜促性腺激素分泌市场的市场规模和预测是多少？

2-在人类绒毛膜促性腺激素分泌市场预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3-人类绒毛膜促性腺激素分泌市场的技术趋势和法律规范是什么？

4-人类绒毛膜促性腺激素分泌市场主要供应商的市场占有率是多少？

5-进入人类绒毛膜促性腺激素分泌市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人口中不孕症病例的增加
      • 加大生育诊所建设投入
      • 提高不孕症治疗意识
    • 抑制因素
      • 人类绒毛膜促性腺激素分泌治疗的高成本
    • 机会
      • 重组技术的进展
      • 促性腺激素分泌疗法在医疗保健领域的出现
    • 任务
      • 人类绒毛膜促性腺激素分泌治疗可能产生的副作用
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章人类绒毛膜促性腺激素分泌市场：副产品

  • 自然提取
  • 重组

第七章依治疗领域分類的人类绒毛膜促性腺激素分泌市场

  • 女性不孕症治疗
  • 男性性腺功能减退症
  • 少精症的治疗

第八章 人类绒毛膜促性腺激素分泌市场：依最终用户分类

  • 不孕不育诊所
  • 调查机构

第九章北美和南美人绒毛膜促性腺激素分泌市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区人类绒毛膜促性腺激素分泌市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲人绒毛膜促性腺激素分泌市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析

第13章竞争产品组合

  • 主要公司简介
    • Biocare Medical, LLC
    • Bristol Myers Squibb Company
    • Cipla Limited
    • Ferring BV
    • Fresenius Kabi AG
    • Intas Pharmaceuticals Ltd.
    • Kamia Biomedical Company
    • Lee Biosolutions, Inc.
    • Life Medicare & Biotech Private Limited
    • Livzon Pharmaceutical Group Inc.
    • Lupin Limited
    • Merck & Co., Inc.
    • Prospec-Tany Technogene Ltd.
    • Qingdao kangyuan Biopharmaceutical Group Co., Ltd.
    • Sanzyme（P）Ltd.
    • Scripps Laboratories, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Sunrise International Labs Ltd.
  • 主要产品系列

第十四章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-6108DAA288E6

[197 Pages Report] The Human Chorionic Gonadotropin Market size was estimated at USD 1.27 billion in 2023 and expected to reach USD 1.37 billion in 2024, at a CAGR 7.53% to reach USD 2.11 billion by 2030.

Global Human Chorionic Gonadotropin Market

KEY MARKET STATISTICS
Base Year [2023] USD 1.27 billion
Estimated Year [2024] USD 1.37 billion
Forecast Year [2030] USD 2.11 billion
CAGR (%) 7.53%
Human Chorionic Gonadotropin Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Human Chorionic Gonadotropin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Human Chorionic Gonadotropin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Human Chorionic Gonadotropin Market, highlighting leading vendors and their innovative profiles. These include Biocare Medical, LLC, Bristol Myers Squibb Company, Cipla Limited, Ferring B.V., Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Kamia Biomedical Company, Lee Biosolutions, Inc., Life Medicare & Biotech Private Limited, Livzon Pharmaceutical Group Inc., Lupin Limited, Merck & Co., Inc., Prospec-Tany Technogene Ltd., Qingdao kangyuan Biopharmaceutical Group Co., Ltd., Sanzyme ( P ) Ltd., Scripps Laboratories, Inc., Sun Pharmaceutical Industries Ltd., and Sunrise International Labs Ltd..

Market Segmentation & Coverage

This research report categorizes the Human Chorionic Gonadotropin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Naturally Extracted
    • Recombinant
  • Therapeutic Area
    • Female Infertility Treatment
    • Male Hypogonadism
    • Oligospermia Treatment
  • End-User
    • Fertility Clinics
    • Research Institutions
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Human Chorionic Gonadotropin Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Human Chorionic Gonadotropin Market?

3. What are the technology trends and regulatory frameworks in the Human Chorionic Gonadotropin Market?

4. What is the market share of the leading vendors in the Human Chorionic Gonadotropin Market?

5. Which modes and strategic moves are suitable for entering the Human Chorionic Gonadotropin Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Human Chorionic Gonadotropin Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidents of infertility among populations
      • 5.1.1.2. Growing investments in the development of fertility clinics
      • 5.1.1.3. Increasing awareness of fertility treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with human chorionic gonadotropin therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in recombinant technology
      • 5.1.3.2. Emergence of gonadotropin therapy in the healthcare sector
    • 5.1.4. Challenges
      • 5.1.4.1. Possible side effects of human chorionic gonadotropin therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Human Chorionic Gonadotropin Market, by Product

  • 6.1. Introduction
  • 6.2. Naturally Extracted
  • 6.3. Recombinant

7. Human Chorionic Gonadotropin Market, by Therapeutic Area

  • 7.1. Introduction
  • 7.2. Female Infertility Treatment
  • 7.3. Male Hypogonadism
  • 7.4. Oligospermia Treatment

8. Human Chorionic Gonadotropin Market, by End-User

  • 8.1. Introduction
  • 8.2. Fertility Clinics
  • 8.3. Research Institutions

9. Americas Human Chorionic Gonadotropin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Human Chorionic Gonadotropin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Human Chorionic Gonadotropin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Biocare Medical, LLC
    • 13.1.2. Bristol Myers Squibb Company
    • 13.1.3. Cipla Limited
    • 13.1.4. Ferring B.V.
    • 13.1.5. Fresenius Kabi AG
    • 13.1.6. Intas Pharmaceuticals Ltd.
    • 13.1.7. Kamia Biomedical Company
    • 13.1.8. Lee Biosolutions, Inc.
    • 13.1.9. Life Medicare & Biotech Private Limited
    • 13.1.10. Livzon Pharmaceutical Group Inc.
    • 13.1.11. Lupin Limited
    • 13.1.12. Merck & Co., Inc.
    • 13.1.13. Prospec-Tany Technogene Ltd.
    • 13.1.14. Qingdao kangyuan Biopharmaceutical Group Co., Ltd.
    • 13.1.15. Sanzyme ( P ) Ltd.
    • 13.1.16. Scripps Laboratories, Inc.
    • 13.1.17. Sun Pharmaceutical Industries Ltd.
    • 13.1.18. Sunrise International Labs Ltd.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. HUMAN CHORIONIC GONADOTROPIN MARKET RESEARCH PROCESS
  • FIGURE 2. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. HUMAN CHORIONIC GONADOTROPIN MARKET DYNAMICS
  • FIGURE 7. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 10. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. HUMAN CHORIONIC GONADOTROPIN MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. HUMAN CHORIONIC GONADOTROPIN MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. HUMAN CHORIONIC GONADOTROPIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY NATURALLY EXTRACTED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 9. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FEMALE INFERTILITY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY MALE HYPOGONADISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY OLIGOSPERMIA TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 13. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. CHINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. INDIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDONESIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. JAPAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. MALAYSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. PHILIPPINES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. SINGAPORE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. SOUTH KOREA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. TAIWAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. THAILAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. VIETNAM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. DENMARK HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. EGYPT HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. FINLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. ISRAEL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. NETHERLANDS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. NIGERIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NORWAY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. POLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. QATAR HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SWEDEN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWITZERLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. TURKEY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. UNITED ARAB EMIRATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. HUMAN CHORIONIC GONADOTROPIN MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 143. HUMAN CHORIONIC GONADOTROPIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 144. HUMAN CHORIONIC GONADOTROPIN MARKET LICENSE & PRICING